| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis
|
Boutros, Andrea
|
|
|
188 |
C |
p. 64-79
|
artikel
|
| 2 |
Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial
|
Geoerger, Birgit
|
|
|
188 |
C |
p. 8-19
|
artikel
|
| 3 |
Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status
|
Alafandi, A.
|
|
|
188 |
C |
p. 122-130
|
artikel
|
| 4 |
CDCA2 promotes melanoma progression by inhibiting ubiquitin-mediated degradation of Aurora kinase A
|
Sun, Wei
|
|
|
188 |
C |
p. 49-63
|
artikel
|
| 5 |
Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients
|
Taylor, Kirsty
|
|
|
188 |
C |
p. 29-38
|
artikel
|
| 6 |
Deep learning detection of melanoma metastases in lymph nodes
|
Jansen, Philipp
|
|
|
188 |
C |
p. 161-170
|
artikel
|
| 7 |
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort
|
Taïeb, Julien
|
|
|
188 |
C |
p. 90-97
|
artikel
|
| 8 |
Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer
|
Xu, Yiquan
|
|
|
188 |
C |
p. 81-89
|
artikel
|
| 9 |
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
|
Zaremba, Anne
|
|
|
188 |
C |
p. 140-151
|
artikel
|
| 10 |
Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer
|
Geukens, Tatjana
|
|
|
188 |
C |
p. 152-160
|
artikel
|
| 11 |
Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids
|
Manacorda, Simona
|
|
|
188 |
C |
p. 98-107
|
artikel
|
| 12 |
Machine learning and patient-reported outcomes for longitudinal monitoring of disease progression in metastatic breast cancer: a multicenter, retrospective analysis
|
Deutsch, Thomas M.
|
|
|
188 |
C |
p. 111-121
|
artikel
|
| 13 |
Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study
|
Bucalo, Agostino
|
|
|
188 |
C |
p. 183-191
|
artikel
|
| 14 |
Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types
|
Musoro, Jammbe Z.
|
|
|
188 |
C |
p. 171-182
|
artikel
|
| 15 |
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
|
Loverix, Liselore
|
|
|
188 |
C |
p. 131-139
|
artikel
|
| 16 |
Primary retroperitoneal sarcoma: A comparison of survival outcomes in specialist and non-specialist sarcoma centres
|
Tirotta, Fabio
|
|
|
188 |
C |
p. 20-28
|
artikel
|
| 17 |
Profile and outcome of cancer patients enrolled in contemporary phase I trials
|
Alouani, Emily
|
|
|
188 |
C |
p. 1-7
|
artikel
|
| 18 |
Re: CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor–T-cell therapy in multiple myeloma
|
Mi, Jian-Qing
|
|
|
188 |
C |
p. 108-110
|
artikel
|
| 19 |
Response to letter entitled: Re: Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment
|
Buisman, Florian E.
|
|
|
188 |
C |
p. 80
|
artikel
|
| 20 |
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
|
Hernando, Jorge
|
|
|
188 |
C |
p. 39-48
|
artikel
|
Tijdschrift beschrijving